You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Catheter Based Cardiovascular Device Retrieval System

    SBC: Onocor LLC            Topic: NHLBI

    During the past decade there has been an exponential growth in the numberscope and complexity of catheter based interventions for structural heart diseaseTranscatheter aortic valve replacementTAVRendovascular aneurysm repairEVARvena caval filters and intracardiac defect closure are all well developed and growing treatment strategiesThe recent FDA approval of left atrial appendageLAAocclusion for a ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Measuring Bladder Permeability with MRI Using a Novel Contrast Agent Formulation

    SBC: Lipella Pharmaceuticals Inc.            Topic: 300

    ABSTRACT This Phase II SBIR proposal leverages the progress made in Phase I on the development of a novel contrast mixture enhanced Tweighted MRI technique as a safesensitiveand objective diagnostic test for the increased permeability in the luminal surface of the urinary bladder in Interstitial Cystitis Bladder Pain SyndromeIC BPSpatientsThe purpose of having such a test is ultimately to allow cl ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Myocardial delivery of MMP inhibiting hydrogels

    SBC: Prohibix, LLC            Topic: NHLBI

    ABSTRACTOvermillion people in the United States currently suffer from heart failure caused by a myocardial infarctionMIand more thansurvivable MIs occur each yearThese troubling statistics amount to an economic burden of over $billion annuallyCurrent clinical treatments for MI include coronary stents and bypass surgeries to overcome the blocked artery and pharmacologic prescription to lessen the w ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Immersive Virtual Reality as a Tool to Improve Police Safety in Adolescents and Adults with ASD

    SBC: Floreo, Inc.            Topic: 103

    Floreo Technology proposes to develop the Police Safety Module (PSM), an innovative, immersive mobile virtual reality (VR) application designed to train police safety in adolescents and adults with autism spectrum disorder (ASD). ASD has been increasing in prevalence over recent years. While much attention has been paid to the causes and early diagnosis of ASD, there remains a clear need for effec ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    The ultimate goal of this Phase I application is to develop novel small moleculebroad spectrum therapeutics against viral infections caused by filoviruses that depend on the PPxY L domain motif for virus egress and spread of infectionEbolaEBOVand MarburgMARVviruses are highly pathogenic and classified as Category Ahigh priority bioterror pathogensAs there are no commercially available therapeutic ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Trigriluzole for the Treatment of Cocaine Addiction

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIDA

    We have discovered trigriluzoleTRLZa tripeptide prodrug improved version of the market drug riluzoleRLZThe glutamic acid lowering properties of RLZ are ideally suited for the treatment of cocaineCOCaddictionand TRLZ is a major advance in delivering riluzole in vivo as validated in multiple in vivo studies in mouseratcynomolgous monkey and humansPhase I PKsafety and tolerability clinical trialTRLZ ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Robot-Assisted Cognitive Training for Socially Isolated Older Adults with Mild Cognitive Impairment

    SBC: Applied Universal Dynamics, Corp.            Topic: NIA

    Project Summary Abstract This project will develop a Socially Assistive RobotSARto provide cognitive trainingin the form of learning to play the pianoto improve cognitive functioning and reduce feelings of loneliness in socially isolated older adultsThe SAR will administer cognitive training via guided practice on a set of standard piano lesson tasks designed to reflect particular cognitive functi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. C.A.R.E.S.: A Mobile Health Program for Alcohol Risk Reduction for an Under-Served College Population

    SBC: LIVE INSPIRED LLC            Topic: 550

    Project Summary AbstractExcessive alcohol use is the third leading preventable cause of death in the U Swith young adults agesshowing the highest rates of hazardous alcohol useCommunity colleges serve overmillion studentscomprisingof all U Scollege studentsCommunity college studentsCCSshow rates of heavy alcohol use similar to students at traditional four year residentialFYRcollegesbut CCS are at ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    ABSTRACT When Cryptococcus is manifested as cryptococcal meningitis (CM), it creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treat. There are now an estimated 2600-7800 US cases and 400,000 cases of CM worldwide annually, with estimated mortality of 15-50% per year. CM is caused when Cryptococcus neoformans, a basidiomycete fungal pathoge ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. An Opioid/Cannabinoid Analgesic that Boosts Pain Relief and Blocks Opiate Reward

    SBC: ElSohly Laboratories, Incorporated            Topic: NIDA

    Project Summary Abuse of prescription opioids and fatalities related to their misuse have increased sharply in recent yearsmaking the development of pain medications with reduced abuse potential a major public health priorityWhen combinedopioids and cannabinoidCBreceptor agonists show analgesic effects appear to be at least additive in a number of pain modelsCannabidiolCBDalthough much less psycho ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government